Skip to main content
Joseph Eder, MD, Oncology, Boston, MA, Yale-New Haven Hospital

JosephPaulEderMD

Oncology Boston, MA

Professor of Medicine, Yale University Cancer Center Chief Medical Officer Parthenon Therapeutics Boston MA

Dr. Eder is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Eder's full profile

Already have an account?

Education & Training

  • Beth Israel Deaconess Medical Center
    Beth Israel Deaconess Medical CenterFellowship, Hematology and Medical Oncology, 1982 - 1985
  • Georgetown University Hospital
    Georgetown University HospitalFellowship, Medical Oncology, 1981 - 1982
  • MedStar Health/Georgetown University Hospital
    MedStar Health/Georgetown University HospitalResidency, Internal Medicine, 1978 - 1981
  • Georgetown University School of Medicine
    Georgetown University School of MedicineClass of 1978

Certifications & Licensure

  • MA State Medical License
    MA State Medical License 1984 - 2025
  • CT State Medical License
    CT State Medical License 2012 - 2023
  • MD State Medical License
    MD State Medical License 1980 - 1996
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Hematology
  • American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2014

Clinical Trials

Publications & Presentations

PubMed

Press Mentions

  • Immunotherapy Drug Shows Potential to Cure Advanced Lung Cancer
    Immunotherapy Drug Shows Potential to Cure Advanced Lung CancerJune 13th, 2019
  • Clinical Trials Take Innovative Approach
    Clinical Trials Take Innovative ApproachApril 3rd, 2018
  • Kolltan Pharmaceuticals Presents Clinical Data for KTN3379 in an Oral Presentation at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting
    Kolltan Pharmaceuticals Presents Clinical Data for KTN3379 in an Oral Presentation at the 2016 American Society of Clinical Oncology (ASCO) Annual MeetingJune 6th, 2016

Professional Memberships

Other Languages

  • German

Hospital Affiliations